Mutations in BRAF have also emerged as a key actionable mutation in non-small cell lung cancer (NSCLC) [5], and several clinical trials are examining the efficacy of BRAF blockade in BRAFmut NSCLC patients. This evidence concerns the gene BRAF and non-small cell lung carcinoma.